Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMPLITUDE-M: Efpeglenatide Monotherapy in T2DM
NCT03353350Phase 3Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Dec 2017
- Primary completion
- Jan 2020
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 5
01
Overview
A Phase 3 trial of efpeglenatide in type 2 diabetes mellitus (T2DM), sponsored by Hanmi Pharmaceutical. Started Dec 2017; status: completed.
02
Drugs
efpeglenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03353350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03353350.